A SYSTEMATIC REVIEW OF TYPES, SYMPTOMS AND TREATMENT OF PSORIASIS
Main Article Content
Keywords
Psoriasis, Skin disorders, Chronic skin disease, types of psoriasis, treatment
Abstract
Psoriasis is a chronic, multisystem inflammatory disease with predominantly skin and joint involvement. It has a bimodal age of onset (16 to 22 and 57 to 60 years)2 and affects both sexes equally. Beyond the physical dimensions of the disease, psoriasis has an extensive emotional and psychosocial effect on patients, affecting social functioning and interpersonal relationships. As a systemic inflammation disease, psoriasis is associated with multiple comorbidities, including cardiovascular disease and malignancy. The diagnosis is primarily clinical and a skin biopsy is seldom required. Depending on the severity of the disease, appropriate treatment can be initiated. First-line treatment for mild to moderate disease involves topical therapies including corticosteroids, vitamin D3 analogues, and combination products. In this review, we have discussed types, symptoms and treatment strategies for Psoriasis.
References
1. Ritchlin, Christopher; Fitzgerald, Oliver. Psoriatic and Reactive Arthritis: A Companion to Rheumatology (1st ed.). Maryland Heights, Miss: Mosby;2007. p.4.
2. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. The Identification and Management of Psoriasis and Associated Comorbidity project team.
3. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85.
4. George S. Current and potential new therapies for the treatment of psoriasis. The Pharmaceutical Journal JUN 2010. [Accessed on August 28, 2017] Available from: https://www.researchgate.net/publication/264236732_Current_and_potential _new_therapies_for_the_treatment_of_psoriasis.
5. Elman SA, Weinblatt M, Merola JF. Targeted therapies for psoriatic arthritis: an update for the dermatologist. Semin Cutan Med Surg, Sep 2018; 37(3): 173-181.
6. Dainichi T., Kitoh A., Otsuka A., Nakajima S., Nomura T., Kaplan D.H., Kabashima K. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat. Immunol. 2018;19:1286–1298.
7. Sawada Y., Gallo R.L. Role of Epigenetics in the Regulation of Immune Functions of the Skin. J. Investig. Dermatol. 2021;141:1157–1166.
8. Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Frontiers in immunology. 2018 Apr 5;9:579.
9. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. Journal of clinical pharmacy and therapeutics. 2000 Jan;25(1):1-0.
10. Molina-Leyva A, Almodovar-Real A, Carrascosa JC, Molina-Leyva I, Naranjo- Sintes R, Jimenez-Moleon JJ. Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis. Anais brasileiros dermatología. 2015 May;90:338-45.
11. Larsabal M, Ly S, Sbidian E, Moyal-Barracco M, Dauendorffer JN, Dupin N, Richard MA, Chosidow O, Beylot-Barry M. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019 Mar;180(3):647-656.
12. Iskandar, I.Y.K.; Parisi, R.; Griffiths, C.E.M.; Ashcroft, D.M.; Global Psoriasis Atlas. Systematic Review Examining Changes over Time and Variation in the Incidence and Prevalence of Psoriasis by Age and Gender. Br. J. Dermatol. 2021, 184, 243–258.
13. Deodhare S.G., General Pathology & Pathology of System, Popular Prakashan, Mumbai, 2nd edition,1553. 1 December 2008.
14. Robbins, Cotran. Pocket Companion to Pathologic Basis of Diseases, W B Saunders Co Ltd; 7th edition (25 January 2006)P.620.
15. Jain S., Gupta O. P. (2005). Dermatitis in Ayurveda with special reference to psoriasis (Kitibha). Aryavaidyan, 28(1): 226-34.
16. Kumar, Abbas, Fausto, Robins, Cotran. Pathological Basis of Disease, Published By Savnders, 7th ed., July 30, 2004. p.1256
17. Vázquez-Herrera NE, Sharma D, Aleid NM, Tosti A. Scalp Itch: A Systematic Review. Skin Appendage Disord, Aug, 2018; 4(3): 187-199.
18. Parrish L. Psoriasis: symptoms, treatments and its impact on quality of life. British Journal of Community Nursing. 2012 Nov;17(11):524-8
19. Böhm D, Stock Gissendanner S, Bangemann K, Snitjer I, Werfel T, Weyergraf A, Schulz W, Jäger B, Schmid‐Ott G. Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. Journal of the European Academy of Dermatology and Venereology. 2013 Feb;27(2):220-6.
20. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni DI, Idi Multipurpose Psoriasis Research on Vital Experiences (Improve) Investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. British Journal of Dermatology. 2004 Sep;151(3):594-9.
21. Schadler ED, OrtelB, MehlisSL. Biologicsforthe primarycare physician: Review and treatment of psoriasis. Dis Mon, Mar, 2019; 65(3): 51-90.
22. Luchetti MM, Benfaremo D, Campanati A, Molinelli E, Ciferri M, Cataldi S, CapeciW, Di Carlo M, Offidani AM, Salaffi F, Gabrielli A. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two- year clinical experience of a dermo-rheumatologic clinic. Clin Rheumatol, Oct 2018; 37(10): 2741-2749.
23. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R.Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology May(2008). 58 (5): 826–850.
24. Palfreeman AC, McNamee KE, McCann FE. "New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast". Drug Design, Development and Therapy. (March 2013) 7: 201–10.
25. Gelf and JM, BerlinJ, VanVoorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol, 2003; 139(11): 1425–9.
26. Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016 Jun 14;3(1):79-82.
27. Tan ES, Chong WS, Tey HL "Nail psoriasis: a review". American Journal of Clinical Dermatology. (December 2012). 13 (6): 375–88.
28. Saleh D, Tanner LS. Guttate Psoriasis. 2023 Jul 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29494104.
29. Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. A systematic review of treatments for guttate psoriasis. Br J Dermatol. 2001 Dec;145(6):891-4.
30. Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013 May 1;87(9):62633.
31. Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Kalb RE (August 2012). "Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation". Journal of the American Academy of Dermatology. 67 (2): 279–88.
31. Raychaudhuri SK, Maverakis E, Raychaudhuri SP (January 2014). "Diagnosis and classification of psoriasis". Autoimmunity Reviews. 13 (4–5): 490–5.
32. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475.
33. Zattra E, Belloni Fortina A, Peserico A, Alaibac M (May 2012). "Erythroderma in the era of biological therapies". European Journal of Dermatology. 22 (2): 167–71.
34. Boyd AS, Menter A. Erythrodermic psoriasis: precipitating factors, course, and prognosis in 50 patients. Journal of the American Academy of Dermatology. 1989 Nov 1;21(5):985-91.
35. Gudjonsson JE, Elder JT, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (2012). "18: Psoriasis". Fitzpatrick's Dermatology in General Medicine(8th ed.). McGraw-Hill.
36. Bell AJ, Duggin G. Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emergency Medicine, 2002; 14: 188-190.
37. Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013 Apr 15;7:339-48.
38. González-Álvarez L, García-Martín JM, García-Pola MJ. Association between geographic tongue and psoriasis: A systematic review and metaanalyses. J Oral Pathol Med. 2019 May;48(5):365-372.
39. Goldenstein-Schainberg C, Favarato MH, Ranza R. Current and relevant concepts in psoriatic arthritis. Rev Bras Reumatol. 2012 Jan-Feb;52(1):98106.
40. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1):S39-S49.
41. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol. 2001;26(4):343-50.
42. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1-10.
43. Campa M, Mansouri B, Warren R, Menter A. A review of biological therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Therapy. 2016;6:1-12.
44. Dhanabal SP, Anand R, MurugananthamN, PraveenTK, Raghu PS. Screening of Wrightia tinctoria leaves for Anti-psoriatic activity. HygeiaJDMed., 2012; 4: 73-78.
45. Dhanabal SP, Priyanka Dwarampudi L, Muruganantham N, Vadivelan R. Evaluation of the anti psoriatic activity of Aloe vera leaf extract using a mouse tail model of psoriasis. Phytother Res., 2012; 26: 617–19.
46. Nardo VD, Gianfaldoni S, Tchernev G, Wollina U, Barygina V, Lotti J, et al. Use of Curcumin in Psoriasis. Open Access Maced J Med Sci. 2018;6(1):218-20.
47. Sánchez M, González-Burgos E, Iglesias I, Gómez-Serranillos MP. Pharmacological Update Properties of Aloe Vera and its Major Active Constituents. Molecules. 2020;25(6).
48. Alzohairy MA. Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment. Evidence-Based Complementary and Alternative Medicine. 2016; 2016:11.
49. SEMON H C G PSORIASIS: (PLATE LXXXIX, XCI) An Atlas of the Commoner Skin Diseases H C G SEMON (Butterworth-Heinemann) (Fifth Edition) 2013 pp 218–21.
50. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research. 2011; 303(1):1-10.
51. Ravindra G. Gaikwad, Anilkumar J. Shinde, Ashok A. Hajare. Herbal Treatment for Management of Psoriasis: An Overview. Research Journal of Pharmacy and Technology. 2022; 15(3):1385-2.
2. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. The Identification and Management of Psoriasis and Associated Comorbidity project team.
3. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85.
4. George S. Current and potential new therapies for the treatment of psoriasis. The Pharmaceutical Journal JUN 2010. [Accessed on August 28, 2017] Available from: https://www.researchgate.net/publication/264236732_Current_and_potential _new_therapies_for_the_treatment_of_psoriasis.
5. Elman SA, Weinblatt M, Merola JF. Targeted therapies for psoriatic arthritis: an update for the dermatologist. Semin Cutan Med Surg, Sep 2018; 37(3): 173-181.
6. Dainichi T., Kitoh A., Otsuka A., Nakajima S., Nomura T., Kaplan D.H., Kabashima K. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat. Immunol. 2018;19:1286–1298.
7. Sawada Y., Gallo R.L. Role of Epigenetics in the Regulation of Immune Functions of the Skin. J. Investig. Dermatol. 2021;141:1157–1166.
8. Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Frontiers in immunology. 2018 Apr 5;9:579.
9. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. Journal of clinical pharmacy and therapeutics. 2000 Jan;25(1):1-0.
10. Molina-Leyva A, Almodovar-Real A, Carrascosa JC, Molina-Leyva I, Naranjo- Sintes R, Jimenez-Moleon JJ. Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis. Anais brasileiros dermatología. 2015 May;90:338-45.
11. Larsabal M, Ly S, Sbidian E, Moyal-Barracco M, Dauendorffer JN, Dupin N, Richard MA, Chosidow O, Beylot-Barry M. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019 Mar;180(3):647-656.
12. Iskandar, I.Y.K.; Parisi, R.; Griffiths, C.E.M.; Ashcroft, D.M.; Global Psoriasis Atlas. Systematic Review Examining Changes over Time and Variation in the Incidence and Prevalence of Psoriasis by Age and Gender. Br. J. Dermatol. 2021, 184, 243–258.
13. Deodhare S.G., General Pathology & Pathology of System, Popular Prakashan, Mumbai, 2nd edition,1553. 1 December 2008.
14. Robbins, Cotran. Pocket Companion to Pathologic Basis of Diseases, W B Saunders Co Ltd; 7th edition (25 January 2006)P.620.
15. Jain S., Gupta O. P. (2005). Dermatitis in Ayurveda with special reference to psoriasis (Kitibha). Aryavaidyan, 28(1): 226-34.
16. Kumar, Abbas, Fausto, Robins, Cotran. Pathological Basis of Disease, Published By Savnders, 7th ed., July 30, 2004. p.1256
17. Vázquez-Herrera NE, Sharma D, Aleid NM, Tosti A. Scalp Itch: A Systematic Review. Skin Appendage Disord, Aug, 2018; 4(3): 187-199.
18. Parrish L. Psoriasis: symptoms, treatments and its impact on quality of life. British Journal of Community Nursing. 2012 Nov;17(11):524-8
19. Böhm D, Stock Gissendanner S, Bangemann K, Snitjer I, Werfel T, Weyergraf A, Schulz W, Jäger B, Schmid‐Ott G. Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. Journal of the European Academy of Dermatology and Venereology. 2013 Feb;27(2):220-6.
20. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni DI, Idi Multipurpose Psoriasis Research on Vital Experiences (Improve) Investigators. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. British Journal of Dermatology. 2004 Sep;151(3):594-9.
21. Schadler ED, OrtelB, MehlisSL. Biologicsforthe primarycare physician: Review and treatment of psoriasis. Dis Mon, Mar, 2019; 65(3): 51-90.
22. Luchetti MM, Benfaremo D, Campanati A, Molinelli E, Ciferri M, Cataldi S, CapeciW, Di Carlo M, Offidani AM, Salaffi F, Gabrielli A. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two- year clinical experience of a dermo-rheumatologic clinic. Clin Rheumatol, Oct 2018; 37(10): 2741-2749.
23. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R.Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology May(2008). 58 (5): 826–850.
24. Palfreeman AC, McNamee KE, McCann FE. "New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast". Drug Design, Development and Therapy. (March 2013) 7: 201–10.
25. Gelf and JM, BerlinJ, VanVoorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol, 2003; 139(11): 1425–9.
26. Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016 Jun 14;3(1):79-82.
27. Tan ES, Chong WS, Tey HL "Nail psoriasis: a review". American Journal of Clinical Dermatology. (December 2012). 13 (6): 375–88.
28. Saleh D, Tanner LS. Guttate Psoriasis. 2023 Jul 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29494104.
29. Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. A systematic review of treatments for guttate psoriasis. Br J Dermatol. 2001 Dec;145(6):891-4.
30. Weigle N, McBane S. Psoriasis. Am Fam Physician. 2013 May 1;87(9):62633.
31. Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Kalb RE (August 2012). "Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation". Journal of the American Academy of Dermatology. 67 (2): 279–88.
31. Raychaudhuri SK, Maverakis E, Raychaudhuri SP (January 2014). "Diagnosis and classification of psoriasis". Autoimmunity Reviews. 13 (4–5): 490–5.
32. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475.
33. Zattra E, Belloni Fortina A, Peserico A, Alaibac M (May 2012). "Erythroderma in the era of biological therapies". European Journal of Dermatology. 22 (2): 167–71.
34. Boyd AS, Menter A. Erythrodermic psoriasis: precipitating factors, course, and prognosis in 50 patients. Journal of the American Academy of Dermatology. 1989 Nov 1;21(5):985-91.
35. Gudjonsson JE, Elder JT, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (2012). "18: Psoriasis". Fitzpatrick's Dermatology in General Medicine(8th ed.). McGraw-Hill.
36. Bell AJ, Duggin G. Acute methyl salicylate toxicity complicating herbal skin treatment for psoriasis. Emergency Medicine, 2002; 14: 188-190.
37. Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R. Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013 Apr 15;7:339-48.
38. González-Álvarez L, García-Martín JM, García-Pola MJ. Association between geographic tongue and psoriasis: A systematic review and metaanalyses. J Oral Pathol Med. 2019 May;48(5):365-372.
39. Goldenstein-Schainberg C, Favarato MH, Ranza R. Current and relevant concepts in psoriatic arthritis. Rev Bras Reumatol. 2012 Jan-Feb;52(1):98106.
40. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1):S39-S49.
41. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol. 2001;26(4):343-50.
42. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CEM, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1-10.
43. Campa M, Mansouri B, Warren R, Menter A. A review of biological therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Therapy. 2016;6:1-12.
44. Dhanabal SP, Anand R, MurugananthamN, PraveenTK, Raghu PS. Screening of Wrightia tinctoria leaves for Anti-psoriatic activity. HygeiaJDMed., 2012; 4: 73-78.
45. Dhanabal SP, Priyanka Dwarampudi L, Muruganantham N, Vadivelan R. Evaluation of the anti psoriatic activity of Aloe vera leaf extract using a mouse tail model of psoriasis. Phytother Res., 2012; 26: 617–19.
46. Nardo VD, Gianfaldoni S, Tchernev G, Wollina U, Barygina V, Lotti J, et al. Use of Curcumin in Psoriasis. Open Access Maced J Med Sci. 2018;6(1):218-20.
47. Sánchez M, González-Burgos E, Iglesias I, Gómez-Serranillos MP. Pharmacological Update Properties of Aloe Vera and its Major Active Constituents. Molecules. 2020;25(6).
48. Alzohairy MA. Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment. Evidence-Based Complementary and Alternative Medicine. 2016; 2016:11.
49. SEMON H C G PSORIASIS: (PLATE LXXXIX, XCI) An Atlas of the Commoner Skin Diseases H C G SEMON (Butterworth-Heinemann) (Fifth Edition) 2013 pp 218–21.
50. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research. 2011; 303(1):1-10.
51. Ravindra G. Gaikwad, Anilkumar J. Shinde, Ashok A. Hajare. Herbal Treatment for Management of Psoriasis: An Overview. Research Journal of Pharmacy and Technology. 2022; 15(3):1385-2.
Article Sidebar
Published
Dec 11, 2024
Article Details
How to Cite
Khushi Prajapati, Dr. Shweta Paroha, & Dr. Pragnesh Patani. (2024). A SYSTEMATIC REVIEW OF TYPES, SYMPTOMS AND TREATMENT OF PSORIASIS. Journal of Population Therapeutics and Clinical Pharmacology, 31(11), 1218-1229. https://doi.org/10.53555/r2vmq387
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Khushi Prajapati
Khyati College of Pharmacy, Plot No.116, B/h. Electrotherm Industries, Nr. Vraj Gopi-2, Palodia, Ahmedabad- 382115
Dr. Shweta Paroha
Associate Professor, Department of Pharmaceutics, Khyati College of Pharmacy, Ahmedabad
Dr. Pragnesh Patani
Principal, Khyati College of Pharmacy, Ahmedabad
How to Cite
Khushi Prajapati, Dr. Shweta Paroha, & Dr. Pragnesh Patani. (2024). A SYSTEMATIC REVIEW OF TYPES, SYMPTOMS AND TREATMENT OF PSORIASIS. Journal of Population Therapeutics and Clinical Pharmacology, 31(11), 1218-1229. https://doi.org/10.53555/r2vmq387